Stock Track | Day One Biopharmaceuticals Plunges 6.74% After Q4 Earnings Miss Analyst Expectations

Stock Track

Feb 25

Day One Biopharmaceuticals Inc. (DAWN) experienced a significant 24-hour plunge of 6.74% in intraday trading on Tuesday. The sharp decline followed the company's release of its fourth-quarter and full-year 2025 financial results.

The biopharmaceutical firm reported a quarterly loss that narrowed from the previous year but fell short of Wall Street estimates. While revenue of $53.7 million exceeded analyst expectations of $49.8 million, the company's quarterly loss of $0.21 per share missed the consensus estimate of $0.18 per share. This earnings miss appears to have driven investor disappointment despite the revenue beat and the company reaffirming its 2026 product revenue guidance of $225 million to $250 million.

Day One's performance highlights the market's sensitivity to earnings results, particularly when companies miss analyst expectations even while showing revenue growth and maintaining future guidance. The stock's decline reflects investor concerns about profitability timelines despite positive developments in the company's OJEMDA product revenue, which showed significant year-over-year growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1173343109"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173343109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173343109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173343109","market":"nz","top_or_hot":-1,"title":"Stock Track | Day One Biopharmaceuticals Plunges 6.74% After Q4 Earnings Miss Analyst Expectations","media":"Stock Track","content":"<p>Day One Biopharmaceuticals Inc. (DAWN) experienced a significant 24-hour plunge of 6.74% in intraday trading on Tuesday. The sharp decline followed the company's release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical firm reported a quarterly loss that narrowed from the previous year but fell short of Wall Street estimates. While revenue of $53.7 million exceeded analyst expectations of $49.8 million, the company's quarterly loss of $0.21 per share missed the consensus estimate of $0.18 per share. This earnings miss appears to have driven investor disappointment despite the revenue beat and the company reaffirming its 2026 product revenue guidance of $225 million to $250 million.</p><p>Day One's performance highlights the market's sensitivity to earnings results, particularly when companies miss analyst expectations even while showing revenue growth and maintaining future guidance. The stock's decline reflects investor concerns about profitability timelines despite positive developments in the company's OJEMDA product revenue, which showed significant year-over-year growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Day One Biopharmaceuticals Plunges 6.74% After Q4 Earnings Miss Analyst Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Day One Biopharmaceuticals Plunges 6.74% After Q4 Earnings Miss Analyst Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 09:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Day One Biopharmaceuticals Inc. (DAWN) experienced a significant 24-hour plunge of 6.74% in intraday trading on Tuesday. The sharp decline followed the company's release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical firm reported a quarterly loss that narrowed from the previous year but fell short of Wall Street estimates. While revenue of $53.7 million exceeded analyst expectations of $49.8 million, the company's quarterly loss of $0.21 per share missed the consensus estimate of $0.18 per share. This earnings miss appears to have driven investor disappointment despite the revenue beat and the company reaffirming its 2026 product revenue guidance of $225 million to $250 million.</p><p>Day One's performance highlights the market's sensitivity to earnings results, particularly when companies miss analyst expectations even while showing revenue growth and maintaining future guidance. The stock's decline reflects investor concerns about profitability timelines despite positive developments in the company's OJEMDA product revenue, which showed significant year-over-year growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DAWN","symbol_name":"Day One Biopharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1173343109","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173343109","pubTimestamp":1771982688,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Day One Biopharmaceuticals Inc. (DAWN) experienced a significant 24-hour plunge of 6.74% in intraday trading on Tuesday. The sharp decline followed the company's release of its fourth-quarter and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DAWN":"Day One Biopharmaceuticals Inc."},"translate_title":"个股追踪|Day One生物制药暴跌6.74%Q4盈利不及分析师预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":1},"content_text":"Day One Biopharmaceuticals Inc. (DAWN) experienced a significant 24-hour plunge of 6.74% in intraday trading on Tuesday. The sharp decline followed the company's release of its fourth-quarter and full-year 2025 financial results.The biopharmaceutical firm reported a quarterly loss that narrowed from the previous year but fell short of Wall Street estimates. While revenue of $53.7 million exceeded analyst expectations of $49.8 million, the company's quarterly loss of $0.21 per share missed the consensus estimate of $0.18 per share. This earnings miss appears to have driven investor disappointment despite the revenue beat and the company reaffirming its 2026 product revenue guidance of $225 million to $250 million.Day One's performance highlights the market's sensitivity to earnings results, particularly when companies miss analyst expectations even while showing revenue growth and maintaining future guidance. The stock's decline reflects investor concerns about profitability timelines despite positive developments in the company's OJEMDA product revenue, which showed significant year-over-year growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}